Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

被引：121

作者：

Kataoka, Keisuke ^{[1
,2
]}

Miyoshi, Hiroaki ^{[3
]}

Sakata, Seiji ^{[4
]}

Dobashi, Akito ^{[4
]}

Couronne, Lucile ^{[5
,6
,7
,8
]}

Kogure, Yasunori ^{[13
]}

Sato, Yasuharu ^{[9
,10
]}

Nishida, Kenji ^{[9
]}

Gion, Yuka ^{[9
]}

Shiraishi, Yuichi ^{[11
]}

Tanaka, Hiroko ^{[11
]}

Chiba, Kenichi ^{[11
]}

Watatani, Yosaku ^{[1
]}

Kakiuchi, Nobuyuki ^{[1
]}

Shiozawa, Yusuke ^{[1
]}

Yoshizato, Tetsuichi ^{[1
]}

Yoshida, Kenichi ^{[1
]}

Makishima, Hideki ^{[1
]}

Sanada, Masashi ^{[12
]}

Onozawa, Masahiro ^{[13
]}

Teshima, Takanori ^{[13
]}

Yoshiki, Yumiko ^{[14
]}

Ishida, Tadao ^{[14
]}

Suzuki, Kenshi ^{[14
]}

Shimada, Kazuyuki ^{[15
]}

Tomita, Akihiro ^{[15
]}

Kato, Motohiro ^{[16
]}

Ota, Yasunori ^{[17
]}

Izutsu, Koji ^{[18
]}

Demachi-Okamura, Ayako ^{[19
]}

Akatsuka, Yoshiki ^{[19
,20
]}

Miyano, Satoru ^{[11
]}

Yoshino, Tadashi ^{[9
]}

Gaulard, Philippe ^{[21
,22
,23
]}

Hermine, Olivier ^{[5
,6
,7
,8
]}

Takeuchi, Kengo ^{[4
]}

Ohshima, Koichi ^{[3
]}

Ogawa, Seishi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan

[2] Natl Canc Ctr, Div Mol Oncol, Res Inst, Tokyo, Japan

[3] Kurume Univ, Dept Pathol, Sch Med, Kurume, Fukuoka, Japan

[4] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo, Japan

[5] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France

[6] INSERM, UMR 1163, Paris, France

[7] CNRS, ERL 8254, Lab Cellular & Mol Mech Hematol Disorders & Thera, Imagine Inst, Paris, France

[8] Paris Descartes Sorbonne Paris Cite Univ, Paris, France

[9] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama, Japan

[10] Okayama Univ, Div Pathophysiol, Grad Sch Hlth Sci, Okayama, Japan

[11] Univ Tokyo, Lab DNA Informat Anal, Ctr Human Genome, Inst Med Sci, Tokyo, Japan

[12] Nagoya Med Ctr, Dept Adv Diag, Clin Res Ctr, Nagoya, Aichi, Japan

[13] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[14] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[15] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan

[16] Natl Ctr Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan

[17] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan

[18] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[19] Aichi Canc Ctr, Div Immunol, Res Inst, Nagoya, Aichi, Japan

[20] Fujita Hlth Univ, Dept Hematol, Sch Med, Toyoake, Aichi, Japan

[21] Henri Mondor Hosp, AP HP, Dept Pathol, Creteil, France

[22] Inst Mondor Rech Biomed, INSERM, U955, Equipe 9, Creteil, France

[23] Paris Est Univ, Creteil, France

来源：

LEUKEMIA | 2019年 / 33卷 / 07期

关键词：

B-CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; IMMUNE CHECKPOINT BLOCKADE; GENETIC ALTERATIONS; SOMATIC MUTATIONS; RECURRENT; PD-L1; REARRANGEMENTS; PEMBROLIZUMAB; EXPRESSION;

D O I：

10.1038/s41375-019-0380-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

引用

页码：1687 / 1699

页数：13

共 38 条

[21] PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase [J].

Kwong, Yok-Lam ;

Chan, Thomas S. Y. ;

Tan, Daryl ;

Kim, Seok Jin ;

Poon, Li-Mei ;

Mow, Benjamin ;

Khong, Pek-Lan ;

Loong, Florence ;

Au-Yeung, Rex ;

Iqbal, Jabed ;

Phipps, Colin ;

Tse, Eric .

BLOOD, 2017, 129 (17) :2437-2442

[22] Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study [J].

Lesokhin, Alexander M. ;

Ansell, Stephen M. ;

Armand, Philippe ;

Scott, Emma C. ;

Halwani, Ahmad ;

Gutierrez, Martin ;

Millenson, Michael M. ;

Cohen, Adam D. ;

Schuster, Stephen J. ;

Lebovic, Daniel ;

Dhodapkar, Madhav ;

Avigan, David ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Cattry, Deepika ;

Zhu, Lili ;

Grosso, Joseph F. ;

Garelik, M. Brigid Bradley ;

Shipp, Margaret A. ;

Borrello, Ivan ;

Timmerman, John .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) :2698-+

[23] EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation [J].

Montes-Moreno, Santiago ;

Odqvist, Lina ;

Diaz-Perez, Julio A. ;

Batlle Lopez, Ana ;

Gonzalez de Villambrosia, Sonia ;

Mazorra, Francisco ;

Castillo, Maria E. ;

Lopez, Mar ;

Pajares, Raquel ;

Garcia, Juan F. ;

Mollejo, Manuela ;

Camacho, Francisca I. ;

Ruiz-Marcellan, Carmen ;

Adrados, Magdalena ;

Ortiz, Nazario ;

Franco, Renato ;

Ortiz-Hidalgo, Carlos ;

Suarez-Gauthier, Ana ;

Young, Ken H. ;

Piris, Miguel A. .

MODERN PATHOLOGY, 2012, 25 (07) :968-982

[24] EBV-positive diffuse large B-cell lymphoma of the elderly [J].

Ok, Chi Young ;

Papathomas, Thomas G. ;

Medeiros, L. Jeffrey ;

Young, Ken H. .

BLOOD, 2013, 122 (03) :328-340

[25] Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas [J].

Palomero, Teresa ;

Couronne, Lucile ;

Khiabanian, Hossein ;

Kim, Mi-Yeon ;

Ambesi-Impiombato, Alberto ;

Perez-Garcia, Arianne ;

Carpenter, Zachary ;

Abate, Francesco ;

Allegretta, Maddalena ;

Haydu, J. Erika ;

Jiang, Xiaoyu ;

Lossos, Izidore S. ;

Nicolas, Concha ;

Balbin, Milagros ;

Bastard, Christian ;

Bhagat, Govind ;

Piris, Miguel A. ;

Campo, Elias ;

Bernard, Olivier A. ;

Rabadan, Raul ;

Ferrando, Adolfo A. .

NATURE GENETICS, 2014, 46 (02) :166-+

[26] PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome [J].

Roemer, Margaretha G. M. ;

Advani, Ranjana H. ;

Ligon, Azra H. ;

Natkunam, Yasodha ;

Redd, Robert A. ;

Homer, Heather ;

Connelly, Courtney F. ;

Sun, Heather H. ;

Daadi, Sarah E. ;

Freeman, Gordon J. ;

Armand, Philippe ;

Chapuy, Bjoern ;

de Jong, Daphne ;

Hoppe, Richard T. ;

Neuberg, Donna S. ;

Rodig, Scott J. ;

Shipp, Margaret A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) :2690-+

[27] Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma [J].

Schmitz, R. ;

Wright, G. W. ;

Huang, D. W. ;

Johnson, C. A. ;

Phelan, J. D. ;

Wang, J. Q. ;

Roulland, S. ;

Kasbekar, M. ;

Young, R. M. ;

Shaffer, A. L. ;

Hodson, D. J. ;

Xiao, W. ;

Yu, X. ;

Yang, Y. ;

Zhao, H. ;

Xu, W. ;

Liu, X. ;

Zhou, B. ;

Du, W. ;

Chan, W. C. ;

Jaffe, E. S. ;

Gascoyne, R. D. ;

Connors, J. M. ;

Campo, E. ;

Lopez-Guillermo, A. ;

Rosenwald, A. ;

Ott, G. ;

Delabie, J. ;

Rimsza, L. M. ;

Wei, K. Tay Kuang ;

Zelenetz, A. D. ;

Leonard, J. P. ;

Bartlett, N. L. ;

Tran, B. ;

Shetty, J. ;

Zhao, Y. ;

Soppet, D. R. ;

Pittaluga, S. ;

Wilson, W. H. ;

Staudt, L. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15) :1396-1407

[28] The future of immune checkpoint therapy [J].

Sharma, Padmanee ;

Allison, James P. .

SCIENCE, 2015, 348 (6230) :56-61

[29] MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers [J].

Steidl, Christian ;

Shah, Sohrab P. ;

Woolcock, Bruce W. ;

Rui, Lixin ;

Kawahara, Masahiro ;

Farinha, Pedro ;

Johnson, Nathalie A. ;

Zhao, Yongjun ;

Telenius, Adele ;

Ben Neriah, Susana ;

McPherson, Andrew ;

Meissner, Barbara ;

Okoye, Ujunwa C. ;

Diepstra, Arjan ;

van den Berg, Anke ;

Sun, Mark ;

Leung, Gillian ;

Jones, Steven J. ;

Connors, Joseph M. ;

Huntsman, David G. ;

Savage, Kerry J. ;

Rimsza, Lisa M. ;

Horsman, Douglas E. ;

Staudt, Louis M. ;

Steidl, Ulrich ;

Marra, Marco A. ;

Gascoyne, Randy D. .

NATURE, 2011, 471 (7338) :377-+

[30]

SWERDLLOW S., 2008, WHO classification of tumours of haematopoietic and lymphoid tissues

← 1 2 3 4 →